ArticlePLOS global public health2026
Practitioner's perspectives on access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practice.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Barriers to Canine Rabies Vaccination in Nigeria: Implications for Rabies Elimination by 2030.Zoonoses and public health · 2026Article
- Completion of rabies post-exposure prophylaxis in Ouagadougou, Burkina Faso, 2021-2023: A cross-sectional analysis of routine data.PLoS neglected tropical diseases · 2026Article
- Barriers to dog bite case management and dog rabies vaccination in Soroti district, Uganda.Frontiers in veterinary science · 2026Article
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
Rabies remains a preventable yet fatal disease that continues to claim lives in low- and middle-income countries due to barriers in accessing post-exposure prophylaxis (PEP). With Gavi, the Vaccine Alliance, now supporting PEP provision in rabies-endemic countries, understanding access barriers is critical. We used mixed-methods to synthesise quantitative data on bite patients (>10,000) captured through an Integrated Bite Case Management platform across four regions of Tanzania, with qualitative data from hotline calls and peer-support chat established among health and veterinary workers from 2018 to 2024. We applied an expanded healthcare access framework comprising six dimensions: availability, accessibility, affordability, accommodation, acceptability, and appropriateness to guide our analyses and assess barriers and facilitators to PEP delivery and uptake in these regions. We identified interconnected barriers to PEP access including recurrent vaccine stockouts (up to 9.2% regionally); long travel distances that were greater for rural patients (on average: 34 vs 13 km for urban patients) who represented the majority at risk; and unaffordable direct and indirect costs leading bite victims to either not start or abandon PEP, incur risky delays or default to traditional remedies. Incorrect bite patient management, including misuse of biologicals sold at unregulated private pharmacies led to preventable deaths, while insufficient vaccination supplies and inadequate service hours, increased risks and costs to patients. Despite these gaps, peer-support mechanisms improved patient management and real-time problem-solving. PEP delivery in Tanzania is undermined by systemic barriers across all access dimensions. Addressing these requires decentralizing vaccine delivery to prioritized accessible facilities, ensuring reliable stock and supplies for intradermal administration, reducing patient costs, strengthening health worker capacity through training and support, and regulating private providers. Lessons from Tanzania highlight the need for context-sensitive, equity-focused strategies to maximize the impact of Gavi's investment and accelerate progress toward Zero by 30.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.